INVA:NGS-Innoviva Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 17.39

Change

0.00 (0.00)%

Market Cap

USD 1.19B

Volume

0.97M

Analyst Target

USD 8.00
Analyst Rating

Verdict

ducovest Verdict
Created with Highstock 5.0.6

Verdict

About

Innoviva Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of small molecule medicines.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
INVA QQQ
  • QQQ
Relative Returns (From:    To: 2025-03-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+8.99 (+1.78%)

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

+11.55 (+1.73%)

USD 76.39B
ARGX argenx NV ADR

+9.23 (+1.53%)

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

+11.35 (+4.69%)

USD 31.94B
ONC BeiGene, Ltd.

+5.88 (+2.27%)

USD 28.70B
RPRX Royalty Pharma Plc

+0.25 (+0.76%)

USD 18.65B
SMMT Summit Therapeutics PLC

-0.66 (-3.17%)

USD 17.01B
UTHR United Therapeutics Corporatio..

+15.70 (+5.11%)

USD 14.37B
INCY Incyte Corporation

-5.85 (-8.62%)

USD 14.22B
MRNA Moderna Inc

+0.09 (+0.26%)

USD 13.74B

ETFs Containing INVA

XSLV Invesco S&P SmallCap Low .. 1.11 % 0.25 %

+0.42 (+1.01%)

USD 0.27B
HSMV First Trust Horizon Manag.. 0.00 % 0.00 %

+0.31 (+1.01%)

USD 0.02B
SIXS 6 Meridian Small Cap Equi.. 0.00 % 0.00 %

+0.47 (+1.01%)

USD 0.09B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.23% 73% C 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.23% 73% C 64% D
Trailing 12 Months  
Capital Gain 17.03% 82% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.03% 82% B 75% C
Trailing 5 Years  
Capital Gain 75.83% 82% B 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 75.83% 82% B 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 13.30% 62% D 66% D+
Dividend Return 13.30% 62% D 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.82% 88% B+ 64% D
Risk Adjusted Return 46.14% 93% A 75% C
Market Capitalization 1.19B 83% B 73% C

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 32.10 18% 21%
Price/Book Ratio 1.63 56% 54%
Price / Cash Flow Ratio 5.95 5% 39%
Price/Free Cash Flow Ratio 13.59 6% 28%
Management Effectiveness  
Return on Equity 3.43% 95% 64%
Return on Invested Capital 19.05% 85% 84%
Return on Assets 8.88% 98% 94%
Debt to Equity Ratio 37.08% 38% 48%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector